Acasia Group

Acasia Group, formerly Cairo Angels, is a premier pan-African investment platform that has evolved from an angel network into a more institutionalized investor bridging the gap between angel capital and institutional Series A rounds. The verified portfolio includes Pharmacy Marts, an Egyptian B2B pharmacy marketplace covering approximately 20 percent of Egyptian pharmacies, which received bridge financing led by Acasia Ventures. Stage focus spans pre-seed through Series A with checks in the $250k to $1M range, and AI is a stated focus. Healthcare interest centers on digital health, pharma-adjacent commerce, and tech-enabled care delivery. The fund was acquired by US-based Sultan Ventures in late 2024, which is reshaping its strategic posture and regional footprint. The right founder for Acasia is an Egyptian, MENA, or pan-African operator building a digital health, healthcare commerce, or care delivery platform with credible regional market wedge and the operational sophistication to scale across multiple African markets. The wrong founder is a deep medtech or therapeutics team, a Series A-plus company looking for an institutional lead at scale, or a non-MENA founder without regional thesis. Intro paths run through Cairo’s tight venture community including Flat6Labs Cairo alumni, the AUC operator network, the broader Sultan Ventures and US-Africa diaspora connections post-acquisition, and frequent co-investors and follow-on partners including HIMAngel, Algebra Ventures, Sawari Ventures, 500 Global MENA, P1 Ventures, and Future Africa. Direct outreach is read but warm intros from cohort founders or angel members materially accelerate diligence. In the pitch, lead with cohort retention, real revenue evidence, the unit economics in local currency with realistic FX assumptions especially given Egyptian and Naira volatility, and a credible cross-border execution story. Be specific about regulatory posture in your primary markets including EDA, MOH Egypt, NAFDAC, KMPDC, and the relevant data protection regimes. Show that you understand pharmacy and clinical workflow realities in your target markets, since Acasia’s pattern recognition on Pharmacy Marts and similar businesses is sharp. Caveats include the strategic transition post-Sultan Ventures acquisition which may shift investment priorities, the competitive landscape for MENA Series A which has intensified, and the reality that Acasia’s check size positions the fund as a syndicate participant rather than sole lead at competitive Series A valuations. For pan-African healthcare commerce and digital health operators, Acasia is a credible regional partner.